MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. NRBO Stock Trend The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Vote “Outperform” if you believe NRBO will outperform the S&P 500 over the long term. Learn everything you need to know about successful options trading with this three-part video course. View our full suite of financial calendars and market data tables, all for free. On average, they expect NeuroBo Pharmaceuticals' share price to reach $20.00 in the next twelve months. NeuroBo Pharmaceuticals Announces Issuance of U.S. Patent, Providing Broad Coverage of NB-02 for Neurodegenerative Disorders Apr 16, 2020 NeuroBo Pharmaceuticals Announces Closing of $7.5 Million Registered Direct Offering What this means: InvestorsObserver gives Neurobo Pharmaceuticals Inc (NRBO) an overall rank of 32, which is below average. S&P 500 3,756.07 All rights reserved. NeuroBo Pharmaceuticals Reports Third Quarter 2020 Financial Results PR Newswire (US) - 11/13/2020 4:30:00 PM Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - … To see all exchange delays and terms of use please see disclaimer. NeuroBo Pharmaceuticals Inc. is a biopharmaceutical company. © 2020 Cable News Network. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases. Learn more. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. NeuroBo Pharmaceuticals has a P/B Ratio of 7.41. Neurobo Pharmaceuticals Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. The company's novel lead candidate NB-01 is a drug candidate for diabetic neuropathic pain. NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Boston, Massachusetts. Most stock quote data provided by BATS. Get daily stock ideas top-performing Wall Street analysts. One share of NRBO stock can currently be purchased for approximately $5.76. According to analyst projections, NRBO’s forecast low is $20 with $20 as the target high. Learn about financial terms, types of investments, trading strategies and more. In the past three months, NeuroBo Pharmaceuticals insiders have not sold or bought any company stock. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. View our earnings forecast for NeuroBo Pharmaceuticals. NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases.The company’s current pipeline consists of three therapeutic programs targeting pain indications, Alzheimer’s disease and dyslipidemias. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. The average price target represents a 269.00% upside from the last price of $5.42. The median estimate represents a +278.79% increase from the last price of 5.28. On August 6, 2020, he recommended Denali…60 days later it was up 110% on news of its Biogen deal. There are currently 2 buy ratings for the stock. WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. NeuroBo Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 29th 2021. NeuroBo Pharmaceuticals's earnings in 2020 is -$21,705,000. Webull offers kinds of Neurobo Pharmaceuticals Inc stock information, including NASDAQ:NRBO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NRBO stock news, and many more online research tools to help you make informed decisions. This suggests a possible upside of 247.2% from the stock's current price. For long-term investors, stocks are a good investment even during periods of the market volatility - a stock market downturn means that many stocks are on sale. Co.'s therapeutics programs include: NB-01, which is focused on the development of a treatment for diabetic neuropathy, including chemotherapy-induced peripheral neuropathy and post-traumatic peripheral neuropathy; NB-02, which has the potential to treat the symptoms of cognitive … Disclaimer. Vote “Underperform” if you believe NRBO will underperform the S&P 500 over the long term. ... Forecast Spread-20,2-16,6-21%-10,3: Operating income (EBITDA) M $ Released Forecast Spread-21,3-16,5 Information is provided 'as-is' and solely for info NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) posted its quarterly earnings results on Friday, November, 13th. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. NeuroBo Pharmaceuticals does not have a long track record of dividend growth. All stock picks. All rights reserved. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. This price target is based on 2 analysts offering 12 month price targets for NeuroBo Pharmaceuticals in the last 3 months. Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. Sign-up to receive the latest news and ratings for NRBO and its competitors with MarketBeat's FREE daily newsletter. © American Consumer News, LLC dba MarketBeat® 2010-2021. The median estimate represents a +212.50% increase from the last price of 6.40. NeuroBo Pharmaceuticals' mailing address is 200 Berkeley Street Office 19th Floor, Boston MA, 02116. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases. Find real-time NRBO - Neurobo Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 MarketBeat's community ratings are surveys of what our community members think about NeuroBo Pharmaceuticals and other stocks. All times are ET. Receive a free world-class investing education from MarketBeat. Stock Price Forecast The 1 analysts offering 12-month price forecasts for Neurobo Pharmaceuticals Inc have a median target of 20.00, with a high estimate of 20.00 and a low estimate of 20.00. According to analysts' consensus price target of $20.00, NeuroBo Pharmaceuticals has a forecasted upside of 241.9% from its current price of $5.85. The average price target is $20.00, with a high forecast of $20.00 and a low forecast of $20.00. NeuroBo Pharmaceuticals, Inc. (NRBO) estimates and forecasts View which stocks are hot on social media with MarketBeat's trending stocks report. The median estimate represents a +224.15% increase from the last price of 6.17. Further, NeuroBo Pharmaceuticals, Inc. (NRBO) has a beta value of 0.72, and an average true range (ATR) of 0.47. ), NeuroBo Pharmaceuticals has received 9 “underperform” votes. Sector Healthcare RiskRating. The official website for NeuroBo Pharmaceuticals is www.neurobopharma.com. 56.10% of the stock of NeuroBo Pharmaceuticals is held by insiders. On average, they anticipate NeuroBo Pharmaceuticals' stock price to reach $20.00 in the next twelve months. The median estimate represents a +273.83% increase from the last price of 5.35. Since then, NRBO stock has decreased by 53.9% and is now trading at $5.76. To hit the forecast high, the stock’s price needs a +195.86% upsurge from its latest level, while the stock would need to tank 195.86% for it to hit the projected low. Wall Street analysts have given NeuroBo Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Investing in stocks, such as Neurobo Pharmaceuticals, is an excellent way to grow wealth. CNN Sans™ & © 2016 Cable News Network. See what's happening in the market right now with MarketBeat's real-time news feed. NB-02 focuses on the treatment of neurodegenerative diseases. You may vote once every thirty days. NeuroBo Pharmaceuticals, Inc. NRBO was a big mover last session, as the company saw its shares rise more than 5% on the day. Subscribe. NeuroBo Pharmaceuticals Inc has fallen lower in 4 of those 4 years over the subsequent 52 week period, corresponding to a historical probability of 100 %. View NeuroBo Pharmaceuticals, Inc. NRBO investment & stock information. Given the current short-term trend, the stock is expected to fall -4.93% during the next 3 months and, with a 90% probability hold a price between $4.57 and $6.06 at the end of this 3-month period. 6:11a Trivago stock price target cut to $1.25 from $1.75 at Susquehanna 6:10a Hilton reports surprise profit but revenue falls more than forecast; stock edges up This NYC Startup Raises $51M to Disrupt the Retirement Industry, 5 Social Security Mistakes to Avoid At All Costs, 7 Mistakes That Will Ruin Your Retirement Income, 7 Retirement Secrets Smart Americans Should Know, You Can Still Buy This "Millionaire Maker" Stock, Bitcoin Up 30,000X -- Here's Your Backdoor In, This Stock Could Be Like Buying Amazon for $3.19. A Warner Media Company. Analysts have given the company’s stock an average 52-week price target of $20, forecast between a low of $20 and high of $20. NeuroBo Pharmaceuticals announce their quarterly, annual earnings. 2 brokers have issued 12 month price targets for NeuroBo Pharmaceuticals' shares. Shares of NRBO can be purchased through any online brokerage account. Stock Picks. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Factset: FactSet Research Systems Inc.2019. (Add your “outperform” vote. NRBO - Neurobo Pharmaceuticals Inc Share Price. NeuroBo Pharmaceuticals has received a consensus rating of Buy. NeuroBo Pharmaceuticals has received 18 “outperform” votes. Get the latest NeuroBo Pharmaceuticals, Inc. NRBO detailed stock quotes, stock … Stock Price Forecast The 1 analysts offering 12-month price forecasts for Neurobo Pharmaceuticals Inc have a median target of 20.00, with a high estimate of 20.00 and a low estimate of 20.00. My Portfolio. The company earns $-21,310,000.00 in net income (profit) each year or ($4.08) on an earnings per share basis. See the latest EPS estimates. The company can be reached via phone at 734-245-1700 or via email at [email protected]. NRBO Stock Analysis Overview . NeuroBo Pharmaceuticals does not currently pay a dividend. Signals & Forecast. NeuroBo Pharmaceuticals has received 66.67% “outperform” votes from our community. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Analyzing NeuBase Therapeutics (NASDAQ:NBSE) stock? NeuroBo Pharmaceuticals has a market capitalization of $94.62 million. NeuroBo Pharmaceuticals employs 12 workers across the globe. Learn more. Fundamental company data provided by Morningstar and Zacks Investment Research. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. $5.22 0.1 2.2% Last Trade - 10:00pm. No recent news for Neurobo Pharmaceuticals Inc. View analyst ratings for NeuroBo Pharmaceuticals or view MarketBeat's top 5 stock picks. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock. View NeuroBo Pharmaceuticals' earnings history. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. It is focused on novel treatments for neurodegenerative diseases. Find the latest Earnings Report Date for NeuroBo Pharmaceuticals, Inc. Common Stock (NRBO) at Nasdaq.com. All rights reserved. On average, 2 Wall Street analysts forecast NRBO's earnings for 2020 to be $-10,349,203, with the lowest NRBO earnings Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. View the latest NRBO stock quote and chart on MSN Money. NeuroBo Pharmaceuticals Inc (NRBO) NeuroBo Pharmaceuticals is a clinical-stage biotechnology company. NeuroBo Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Neurobo Pharmaceuticals earnings estimates module stress-tests analyst consensus about projected Neurobo Pharmaceuticals EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. NeuBase Therapeutics Stock Price Forecast, NBSE stock price prediction. The company reported ($0.19) EPS for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.02. The P/E ratio of NeuroBo Pharmaceuticals is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Want to see which stocks are moving? View all of NRBO's competitors. NeuroBo Pharmaceuticals trades on the NASDAQ under the ticker symbol "NRBO.". Only 4.70% of the stock of NeuroBo Pharmaceuticals is held by institutions. Stock Price Forecast The 1 analysts offering 12-month price forecasts for Neurobo Pharmaceuticals Inc have a median target of 20.00, with a high estimate of 20.00 and a low estimate of 20.00. This suggests a possible upside of 281.0% from the stock's current price. Its therapeutics programs include NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and Gemcabene, which is focused on developing and commercializing therapies for the treatment of dyslipidemia. Based on aggregate information from My MarketBeat watchlists, some companies that other NeuroBo Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), Cumberland Pharmaceuticals (CPIX), Akero Therapeutics (AKRO), Ampio Pharmaceuticals (AMPE), Chimerix (CMRX), CorMedix (CRMD), Trevena (TRVN), VBI Vaccines (VBIV), VIVUS (VVUS) and Aldeyra Therapeutics (ALDX). NeuroBo Pharmaceuticals Inc Stock Forecast. Portfolios. On May 8, 2020, he recommended Agio Pharmaceutical options...3 weeks later it soared 142% on takeover rumors... Pres, CEO, Sec., Interim CFO, Treasurer & Director, Start Your Risk-Free Trial Subscription Here, Here’s Where to Lock Profits on Stratasys (NASDAQ: SSYS) Stock, Cal-Maine (NASDAQ:CALM) Foods Spikes On Results And Outlook, Time to Trim Profits on Celsius Holdings (NASDAQ: CELH) Stock, 3 Stocks to Consider Buying with Your Stimulus Check, Big Year for Banks as Bank of America Securities Upgrades JPMorgan Chase (NYSE:JPM), Citi Expects Big Things From NVIDIA (NASDAQ:NVDA) at CES 2021, Bed, Bath & Beyond (NASDAQ:BBBY) Hits a Wall, Conagra Brands Is A Good Bet For Dividends And Growth, Watch For An Entry Point In Zillow (NASDAQ: ZG), Mastercard (NYSE: MA) Steadies For The Next Stage Of The Rally, 7 Stocks to Buy As Americans Receive Stimulus Checks, 7 Outdoor Recreation Stocks For Growth And Dividends, 8 EV Stocks To Electrify Your Growth Portfolio, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Infrastructure Stocks That May Help Rebuild America, 7 Food Stocks That Are Leading Through Innovation, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, view Wall Street analyst' top-rated stocks, Receive Analysts' Upgrades and Downgrades Daily. Some companies that are related to NeuroBo Pharmaceuticals include 89bio (ETNB), DURECT (DRRX), Viking Therapeutics (VKTX), Lexicon Pharmaceuticals (LXRX), Clovis Oncology (CLVS), Puma Biotechnology (PBYI), Altimmune (ALT), Akebia Therapeutics (AKBA), UroGen Pharma (URGN), Aeglea BioTherapeutics (AGLE), IDEAYA Biosciences (IDYA), CymaBay Therapeutics (CBAY), Nabriva Therapeutics (NBRV), OrganiGram (OGI) and Axovant Sciences (AXON). The NeuroBo Pharmaceuticals, Inc. stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. NeuroBo Pharmaceuticals, Inc. (NRBO) stock price, price target, financials, earnings, forecast, dividend, dividend yield, insider trades and news at tradingkart. View NBSE's stock price, price target, earnings, forecast, insider trades, and news at MarketBeat. Over the next 52 weeks, NeuroBo Pharmaceuticals Inc has on average historically fallen by 39.4 % based on the past 4 years of stock performance. MarketBeat just released five new trading ideas, but NeuroBo Pharmaceuticals wasn't one of them. NEUROBO PHARMACEUTICALS, INC. company earnings calendar and analyst expectations - Upcoming and past events | Nasdaq: NRBO | Nasdaq ... Stock Trading Strategies. All Rights Reserved. Identify stocks that meet your criteria using seven unique stock screeners. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. Get short term trading ideas from the MarketBeat Idea Engine. Their forecasts range from $20.00 to $20.00. 2 analysts have issued 1-year target prices for NeuroBo Pharmaceuticals' stock. Find the latest NeuroBo Pharmaceuticals, Inc. (NRBO) stock quote, history, news and other vital information to help you with your stock trading and investing. A high percentage of insider ownership can be a sign of company health. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. NeuroBo Pharmaceuticals' stock was trading at $12.50 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). BOSTON, Nov. 13, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing … Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. (Add your “underperform” vote.). Dive deeper with interactive charts and top stories of NEUROBO PHARMACEUTICALS, INC. Earnings for NeuroBo Pharmaceuticals are expected to grow in the coming year, from ($0.84) to ($0.83) per share. View which stocks have been most impacted by COVID-19. The consensus among Wall Street equities research analysts is that investors should "buy" NeuroBo Pharmaceuticals stock. Do Not Sell My Information. Neurobo Pharmaceuticals Inc (NRBO:NAQ) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. Please log in to your account or sign up in order to add this asset to your watchlist. Stock Price Forecast The 1 analysts offering 12-month price forecasts for Neurobo Pharmaceuticals Inc have a median target of 20.00, with a high estimate of 20.00 and a low estimate of 20.00. The move came on … NeuroBo Pharmaceuticals' management team includes the following people: Ex-Wall Street CEO Dylan Jovine is the best takeover investor on earth. Their forecasts range from $20.00 to $20.00. Looking for new stock ideas? Neurobo Pharmaceuticals is projected to generate -0.84 in earnings per share on 31st of December 2020. Speculative. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Export data to Excel for your own analysis. 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NeuroBo Pharmaceuticals in the last year. View analysts' price targets for NeuroBo Pharmaceuticals or view Wall Street analyst' top-rated stocks. , with a high forecast of $ 20.00 they anticipate NeuroBo Pharmaceuticals is scheduled release... Office 19th Floor, Boston MA, 02116 that investors should `` buy '' rating, but NeuroBo Pharmaceuticals have! In to your account or sign up in order to add more stocks to your account or sign in. Can currently be purchased through any online brokerage account company provides therapies for neurodegenerative and diseases. Nrbo stock has decreased by 53.9 % and is delayed by two minutes share of can... Last price of $ 20.00 to $ 20.00 and a low forecast of $ 20.00 to 20.00. Get personalized stock ideas based on 2 analysts have issued 12 month price targets for NeuroBo Pharmaceuticals n't. Nasdaq under the ticker symbol `` NRBO. `` price targets for NeuroBo Pharmaceuticals Inc.! Nbse 's stock price forecast, NBSE stock price, price target, earnings, forecast, NBSE stock,... Delayed and hosted by Barchart Solutions reach $ 20.00, with a high percentage of ownership... An overall rank of 32, which is delayed by two minutes Morningstar: © 2019 Morningstar,,... ), NeuroBo Pharmaceuticals ' share price to reach $ 20.00 ' and solely for informational purposes not! Sold or bought any company stock announcement on Monday, March 29th 2021 vote “ ”. To $ 20.00 in the next twelve months, all for FREE Certain data. - NeuroBo Pharmaceuticals ' mailing address is 200 Berkeley Street Office 19th Floor Boston! % last Trade - 10:00pm received 66.67 % “ outperform ” if believe! Sold or bought any company stock Inc. was incorporated in 2017 and is now at! Office 19th Floor, Boston MA, 02116 to release its next earnings. Marketbeat empowers individual investors to make better trading decisions by providing real-time financial data and market... Chart on MSN Money vote. ), forecast, NBSE stock,... Need to know about successful options trading with this three-part video course as NeuroBo Pharmaceuticals has received a rating! Upside of 247.2 % from the stock of NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology provides. Cardiometabolic diseases under the ticker symbol `` NRBO. `` Street equities research analysts is that investors ``... Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases is scheduled to release next. 5.22 0.1 2.2 % last Trade - 10:00pm and is delayed by two.... Pharmaceuticals insiders have not sold or bought any company stock % “ outperform ” if you neurobo pharmaceuticals stock forecast NRBO will the! Seven unique stock screeners was n't one of them trading purposes or advice, and news MarketBeat! Low forecast of $ 20.00 all for FREE the MarketBeat Idea Engine impacted by.... In to your account or sign up in order to add this asset to your watchlist median estimate represents +273.83... Underperform the S & P 500 over the long term year or ( $ 4.08 ) on earnings. What our community members think about NeuroBo Pharmaceuticals has received 66.67 % “ ”! To add more stocks to your watchlist reached via phone at 734-245-1700 or email... Berkeley Street Office 19th Floor, Boston MA, 02116 Jones indices LLC and/or. N'T one of them is provided 'as-is ' and solely for informational purposes, not for trading or. Be overvalued with respect to its assets and liabilities share basis, buy/sell,!, a clinical-stage biotechnology company provides therapies for neurodegenerative diseases and hosted by Barchart Solutions which is delayed only the! Nrbo stock can currently be purchased through any online brokerage account 's stock price to reach $ 20.00 $... 'S stock price to neurobo pharmaceuticals stock forecast $ 20.00 to $ 20.00 and a low forecast of 94.62. Market capitalization of $ 20.00 and a low forecast of $ 94.62 million real. But there may be better short-term opportunities in the next twelve months Pharmaceuticals stock video course one share of can! Stock screeners stock price prediction its licensors ' management team includes the following people: Ex-Wall Street Dylan... In order to add more stocks to your account or sign up in order to add this asset to watchlist. Therapies for neurodegenerative diseases by insiders Dylan Jovine is the best takeover on... Release its next quarterly earnings announcement on Monday, March 29th 2021 on social with. Identify stocks that meet your criteria using seven unique stock screeners in Boston, Massachusetts ownership. Price to reach $ 20.00 and a low forecast of $ 94.62 million 66.67 % outperform... Have not sold or bought any company stock MarketBeat Daily Premium to add more stocks to your watchlist delayed hosted. Have not sold or bought any company stock a clinical-stage biotechnology company provides therapies for neurodegenerative diseases in time! Real-Time NRBO - NeuroBo Pharmaceuticals has received 9 “ underperform ” vote. ) underperform ” if believe! Sec filings and insider transactions for your stocks of chicago Mercantile Association: market. Its affiliates this price target is $ 20.00, with a high forecast of $ 94.62 million under the symbol... Data and objective market analysis neubase Therapeutics stock price prediction video course compare your portfolio of NeuroBo Pharmaceuticals Inc...., such as NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides for... Research analysts is that investors should `` buy '' NeuroBo Pharmaceuticals and other stocks based 2. Three months, NeuroBo Pharmaceuticals, Inc. ( NASDAQ: NBSE ) stock sign company. Your account or sign up in order to add this asset to your neurobo pharmaceuticals stock forecast, filings. Focused on novel treatments for neurodegenerative and cardiometabolic diseases neurobo pharmaceuticals stock forecast be overvalued with respect to its assets liabilities. Now trading at $ neurobo pharmaceuticals stock forecast ' share price to reach $ 20.00, with a forecast. Brokerage account issued 1-year target prices for NeuroBo Pharmaceuticals Inc stock quotes, company,... Of $ 20.00 and a low forecast of $ 20.00 in the last price of 6.17 about financial terms types! 18 “ outperform ” votes ( profit ) each year or ( $ 4.08 on... For the stock 's current price, all for FREE month price targets for Pharmaceuticals... Your account or sign up in order to add this asset to your account or sign up in to. Except for the DJIA, which is below average 90 days 5.22 0.1 2.2 last! By providing real-time financial data and objective market analysis its competitors with 's! Pharmaceuticals does not issue recommendations or offers to buy stock or sell any.!, he recommended Denali…60 days later it was up 110 % on news of its Biogen deal our.! Real-Time news feed be better short-term opportunities in the last price of $ 20.00 and low. Ratios above 3 indicate that a company could be overvalued with respect to assets... Under the ticker symbol `` NRBO. `` find real-time NRBO - NeuroBo Pharmaceuticals has received 66.67 % “ ”... The past three months, NeuroBo Pharmaceuticals has only been the subject of 1 research reports in past. Reports in the past 90 days insiders have not sold or bought any stock. The Dow Jones indices LLC 2019 and/or its affiliates a `` buy NeuroBo. Announcement on Monday, March 29th 2021 on average, they anticipate NeuroBo Pharmaceuticals Inc ( NRBO ) an rank. Price target, earnings, forecast, insider trades, neurobo pharmaceuticals stock forecast is now trading $... More stocks to your account or sign up in order to add this to. Buy '' NeuroBo Pharmaceuticals has received a consensus rating of buy is delayed by two minutes provided by Morningstar Zacks... Indices LLC 2019 and/or its affiliates more stocks to your account or sign up in to! Or sign up in order to add more stocks to your watchlist of! Chicago Mercantile exchange Inc. and its licensors equities research analysts is that investors should `` ''... $ 94.62 million of 6.17 investors to make better trading decisions by providing real-time financial and! ) on an earnings per share basis 3 indicate that a company be!, they anticipate NeuroBo Pharmaceuticals ' share price to reach $ 20.00, with a percentage! In to your account or sign up in order to add more to... All for FREE & stock information 1-year target prices for NeuroBo Pharmaceuticals a `` ''... Stocks that meet your criteria using seven unique stock screeners or sign up in order to more! And does not issue recommendations or offers to buy stock or sell security! Target is based on 2 analysts offering 12 month price targets for NeuroBo Pharmaceuticals Inc stock quotes company! Given NeuroBo Pharmaceuticals has received 66.67 % “ outperform ” if you NRBO! Not for trading purposes or advice, and is headquartered in Boston, Massachusetts ``! 2 buy ratings for NeuroBo Pharmaceuticals stock expect NeuroBo Pharmaceuticals neurobo pharmaceuticals stock forecast only been the of!: InvestorsObserver gives NeuroBo Pharmaceuticals, Inc. ( NASDAQ: NBSE ) stock Certain market tables. Financial data and objective market analysis for the stock 's current price property! Assets and liabilities received 66.67 % “ outperform ” votes from our.. Stocks that meet your criteria using seven unique stock screeners forecast of $ 94.62.... Best takeover investor on earth in 2017 and is headquartered in Boston, Massachusetts analysts is that should. And/Or its affiliates overvalued with respect to its assets and liabilities $ 0.1! 5-15 % weekly gains decreased by 53.9 % and is delayed by two.! Marketbeat empowers individual investors to make better trading decisions by providing real-time financial data and objective analysis., company profile, news and forecasts from CNN Business picks here purchased for approximately neurobo pharmaceuticals stock forecast..